Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity

Current Biology

Volumn 15, Issue 2, 2005, Pages 166-170

  Newman, Edmund N C ^a   Holmes, Rebecca K ^a   Craig, Heather M ^a   Klein, Kevin C ^b   Lingappa, Jaisri R ^b   Malim, Michael H ^a   Sheehy, Ann M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CEM15 PROTEIN, HUMAN; CYTIDINE DEAMINASE; DEAMINASE; PROTEIN; REPRESSOR PROTEIN; VIF PROTEIN;

ARTICLE; CELL CULTURE; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MUTATION; PHYSIOLOGY; PROTEIN MOTIF; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS; VIRION;

AMINO ACID MOTIFS; ANTIVIRAL AGENTS; CELLS, CULTURED; CYTIDINE DEAMINASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE PRODUCTS, VIF; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION; NUCLEOSIDE DEAMINASES; PROTEIN STRUCTURE, TERTIARY; PROTEINS; REPRESSOR PROTEINS; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 12544256041     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cub.2004.12.068     Document Type: Article

References (30)

1. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 418:2002;646-650
2. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell. 113:2003;803-809
3. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 424:2003;99-103
4. Lecossier D., Bouchonnet F., Clavel F., Hance A.J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 300:2003;1112
5. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 424:2003;94-98
6. Stopak K., de Noronha C., Yonemoto W., Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell. 12:2003;591-601
7. Sheehy A.M., Gaddis N.C., Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:2003;1404-1407
8. Marin M., Rose K.M., Kozak S.L., Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:2003;1398-1403
9. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279:2004;7792-7798
10. Conticello S.G., Harris R.S., Neuberger M.S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2003;2009-2013
11. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 114:2003;21-31
12. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 302:2003;1056-1060
13. Kao S., Khan M.A., Miyagi E., Plishka R., Buckler-White A., Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77:2003;11398-11407
14. Bhattacharya S., Navaratnam N., Morrison J.R., Scott J., Taylor W.R. Cytosine nucleoside/nucleotide deaminases and apolipoprotein B mRNA editing. Trends Biochem. Sci. 19:1994;105-106
15. MacGinnitie A.J., Anant S., Davidson N.O. Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity. J. Biol. Chem. 270:1995;14768-14775
16. Petersen-Mahrt S.K., Harris R.S., Neuberger M.S. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature. 418:2002;99-103
17. Harris R.S., Petersen-Mahrt S.K., Neuberger M.S. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell. 10:2002;1247-1253
18. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14:2004;1392-1396
19. Liddament M.T., Brown W.L., Schumacher A.J., Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14:2004;1385-1391
20. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics. 79:2002;285-296
21. Wiegand H.L., Doehle B.P., Bogerd H.P., Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23:2004;2451-2458
22. Svarovskaia E.S., Xu H., Mbisa J.L., Barr R., Gorelick R.J., Ono A., Freed E.O., Hu W.S., Pathak V.K. Human APOBEC3G is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279:2004;35822-35828
23. Luo K., Liu B., Xiao Z., Yu Y., Yu X., Gorelick R., Yu X.F. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78:2004;11841-11852
24. Zennou V., Perez-Caballero D., Gottlinger H., Bieniasz P.D. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 78:2004;12058-12061
25. Schafer A., Bogerd H.P., Cullen B.R. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology. 328:2004;163-168
26. Shindo K., Takaori-Kondo A., Kobayashi M., Abudu A., Fukunaga K., Uchiyama T. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 278:2003;44412-44416
27. Turelli P., Mangeat B., Jost S., Vianin S., Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science. 303:2004;1829
28. Rosler C., Kock J., Malim M.H., Blum H.E., von Weizsacker F. Comment on "Inhibition of hepatitis B virus replication by APOBEC3G" Science. 305:2004;1403
29. Shinkura R., Ito S., Begum N.A., Nagaoka H., Muramatsu M., Kinoshita K., Sakakibara Y., Hijikata H., Honjo T. Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat. Immunol. 5:2004;707-712
30. Simon J.H., Malim M.H. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J. Virol. 70:1996;5297-5305